Tacrolimus 0.1% vs mometasone furoate topical treatment in allergic contact hand eczema: a prospective randomized clinical study.

Tacrolimus is a macrolide immunosuppressant that has been demonstrated to inhibit T-lymphocyte activation without the side-effects of corticosteroids. The safety profile of tacrolimus makes it a promising therapeutic option for dermatitis. To evaluate and compare the therapeutic ability of tacrolimus 0.

Skin diseases in Greek and immigrant children in Athens.

Objectives: This study aimed to characterize the spectrum of skin diseases affecting children in Greece.

Methods: We retrospectively studied data for 4071 children, aged 0-12 years, who were examined and diagnosed with dermatoses at the outpatient clinic of a university dermatological hospital between December 2005 and August 2007. To evaluate changes in disease patterns, these data were compared with data for a cohort of 12,700 children diagnosed with skin diseases at the same clinic two to three decades earlier (in 1977, 1980, and 1983).

Childhood- and later-onset vitiligo have diverse epidemiologic and clinical characteristics.

Background: Vitiligo onset during childhood is common. There are limited data regarding childhood-onset vitiligo.

Objective: We sought to provide an epidemiologic and clinical comparison between childhood- and later-onset vitiligo.

Psoriasis in children: a retrospective analysis.

Background: Few epidemiological studies are available on childhood psoriasis.

Methods: Between 2005 and 2008, information was collected about all children diagnosed with psoriasis in the Pediatric Dermatology Unit of Andreas Sygros Skin Hospital, in Athens, Greece.

Results: A total of 125 children with psoriasis were examined, the male to female ratio was 1.

Prognostic factors for the response to treatment in males with genital warts.

Background: Factors predicting an unfavourable course of genital warts to treatment have not been determined.

Materials And Methods: Behavioural and baseline disease characteristics were recorded from 246 males with anogenital warts. Urethral swabs were obtained and examined using the Hybrid Capture 2 Microplate assay.

Tacrolimus ointment 0.1% in the treatment of allergic contact eyelid dermatitis.

Background: Tacrolimus inhibits T-lymphocyte activation and dermal Langerhans' cells, without the side-effects of corticosteroids. The safety profile of tacrolimus makes it a promising therapeutic option for dermatitis affecting the delicate periorbital skin.

Objective: To access the efficacy and tolerability of tacrolimus ointment 0.

Clinical features and natural history of acquired cold urticaria in a tertiary referral hospital: a 10-year prospective study.

Background: Acquired cold urticaria (ACU) represents a heterogeneous group of disorders that share a common clinical feature: the development of urticaria or angioedema after cold exposure. We present epidemiological and clinical data of subjects with ACU, natural progression and we examine possible parameters that could correlate with disease severity.

Methods: During a 10-year period in all subjects with ACU, detailed record of personal history, laboratory testing, cold stimulation testing (CST), atopy assessment and disease severity took place.

Photoallergic contact dermatitis: the 15-year experience of a tertiary reference center in a sunny Mediterranean city.

Photoallergic contact dermatitis (PACD) represents an important entity of photodermatoses while photopatch testing is the main diagnostic tool. The main goal of this study is to evaluate retrospectively the prevalence of photoallergic reactions and the offending agents in Athens during a 15-year period. The medical records of all patients with possible PACD between 1992 and 2006 were examined.

Comparison of cryotherapy to imiquimod 5% in the treatment of anogenital warts.

The aim of this study was to compare the efficacy of crotherapy versus imiquimod 5% in the treatment of anogenital warts. Eighty HIV-negative males were included in the analysis; 35 of them were treated with imiquimod 5% three times a week for 6-10 hours and 45 of them with cryotherapy once in three weeks. Follow-up appointments were arranged every month for the first three months and then at six and 12 months, or in between whenever the patients noticed any signs of recurrence.